Cempra Inc.’s stock (NASDAQ:CEMP) lost 28 percent of its value Friday to close at $19.29, down $7.49, as investors balked at infusion-site pain reactions reported in the otherwise successful, second phase III trial with solithromycin for community-acquired bacterial pneumonia (CABP).